

PMR Public Report

| | | | |
|-----------------------------|----------------------------------|-----------------------------------------------|----------|
| Operation Number | AR-L1196 | Chief of Operations Validation Date | 10/21/21 |
| Year- PMR Cycle | First period Jan-Jun 2021 | Division Chief Validation Date | |
| Last Update | 10/06/21 | Country Representative Validation Date | |
| PMR Validation Stage | Validated by Chief of Operations | | |

Basic Data

Operation Profile

| | | | |
|---------------------------|--------------------------------------------------------------------------------------|-----------------------------------------|-------------------------------------|
| Operation Name | MULTIPHASE PRIMARY HEALTH CARE PROGRAM FOR MANAGING CHRONIC NONCOMMUNICABLE DISEASES | Loan Number | 3772/OC-AR |
| Executing Agency | MINISTERIO DE SALUD | Sector/Subsector | HEALTH-DISEASE PREVENTION & CONTROL |
| Team Leader | TRISTAO, IGNEZ M. | Overall Stage | Fully Disbursed |
| Operation Type | Loan Operation | Country | Argentina |
| Lending Instrument | Investment Loan | Convergence related Operation(s) | |
| Borrower | NACION ARGENTINA | | |


Environmental and Social Safeguards

| | | | |
|-------------------------------------------------|---|------------------------------------------------------------------|----|
| Impacts Category | C | Was/Were the objective(s) of this operation reformulated? | NO |
| Safeguard Performance Rating | | Date of approval | |
| Safeguard Performance Rating - Rationale | | | |

Financial Data

| Item | Total Cost and Source | | | | | Available Funds (US\$) | | | |
|------------|-----------------------|-------------|-------------------|------------------------|---------------------|------------------------|----------------------|---------|--------------------|
| | Original IDB | Current IDB | Local Counterpart | Co-Financing / Country | Total Original Cost | Current IDB | Disb. Amount to Date | % Disb | Undisbursed Amount |
| AR-L1196 | 100,000,000 | 100,000,000 | 66,000,000 | 0 | 166,000,000 | 100,000,000 | 100,000,000 | 100.00% | 0 |
| Aggregated | 100,000,000 | 100,000,000 | 66,000,000 | 0 | 166,000,000 | 100,000,000 | 100,000,000 | 100.00% | 0 |

Expense Categories by Loan Contract (cumulative values)



PMR Public Report

RESULTS MATRIX

General Development Objectives

General Development Objectives Nbr. 0: Contribuir a la reducción de la morbilidad por enfermedades crónicas no transmisibles en Argentina, con énfasis en la población con cobertura pública exclusiva

Observation:

| | Indicator | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | | Target |
|-----|--------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|------------------------------|---|--------|
| 0.1 | Hipertensos entre 40 y 65 años con tratamiento farmacológico, sobre el total de hipertensos del mismo rango etario | Porcentaje | 62.30 | 2013 | 2021 | P | 67.20 |
| | | | | | | A | |

Details

Means of verification: Informe de evaluación de impacto del Programa REDES

Observations: Con base en las Encuestas Nacionales de Factores de Riesgo. La próxima está prevista para 2018

Pro-Gender No **Pro-Ethnicity** No

The General Development objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO) No

| | Indicator | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | | Target |
|-----|-------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|------------------------------|---|--------|
| 0.2 | Diabéticos entre 40 y 65 años con tratamiento farmacológico, sobre el total de diabéticos del mismo rango etario. | Porcentaje | 47.50 | 2013 | 2021 | P | 52.10 |
| | | | | | | A | |

Details

Means of verification: Informe de evaluación de impacto del Programa REDES

Pro-Gender No **Pro-Ethnicity** No

The General Development objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO) No

| | Indicator | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | | Target |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|------------------------------|---|--------|
| 0.3 | Mujeres entre 50 y 69 años con diagnóstico de cáncer de mama en estadio temprano, sobre el total de mujeres registradas del mismo rango etario | Porcentaje | 43.20 | 2015 | 2021 | P | 49.40 |
| | | | | | | A | |

PMR Public Report

RESULTS MATRIX

General Development Objectives

| | | | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|------------|---------------|------|------|--|--|
| 0.3 | con diagnóstico de cáncer de mama. | Porcentaje | 43.20 | 2015 | 2021 | | |
| Details | | | | | | | |
| Means of verification: Sistema de Información de Tamizaje | | | | | | | |
| Pro-Gender | | No | Pro-Ethnicity | | No | | |
| The General Development objective indicator target is expected to be observed by the operation's "Fully Justified" date inConvergence (CO) | | No | | | | | |

| | | | | | | | |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|------------------------------|---|--------|
| | Indicator | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | | Target |
| 0.4 | Mujeres entre 30 y 64 años con diagnóstico de lesión precancerosa de alto grado o cáncer cervicouterino en estadio temprano , sobre el estimado del total de mujeres del mismo rango etario con lesiones precancerosas y cáncer cervicouterino . | Porcentaje | 10.00 | 2015 | 2021 | P | 18.00 |
| | | | | | | A | |

| | | | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------|--|----|---------------|--|----|--|--|
| Details | | | | | | | |
| Means of verification: Sistema de Información de Tamizaje | | | | | | | |
| Pro-Gender | | No | Pro-Ethnicity | | No | | |
| The General Development objective indicator target is expected to be observed by the operation's "Fully Justified" date inConvergence (CO) | | No | | | | | |

| | | | | | | | |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|------------------------------|---|--------|
| | Indicator | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | | Target |
| 0.5 | Personas entre 50 y 75 años con diagnóstico de lesiones precancerosas o cáncer colorrectal estadio temprano , sobre el total de personas tamizadas del mismo rango etario con diagnóstico de lesiones precancerosas o cáncer colorrectal . | Porcentaje | 51.00 | 2015 | 2021 | P | 60.00 |
| | | | | | | A | |

| | | | | | | | |
|-----------------------------------------------------------|--|----|---------------|--|----|--|--|
| Details | | | | | | | |
| Means of verification: Sistema de Información de Tamizaje | | | | | | | |
| Pro-Gender | | No | Pro-Ethnicity | | No | | |

PMR Public Report

RESULTS MATRIX

General Development Objectives

The General Development
bjective indicator target is
expected to be observed by
the operation's "Fully
Justified" date
in Convergence (CO)

No

| | Indicator | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | | Target |
|-----|--------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|------------------------------|---|--------|
| 0.6 | Tiempo promedio que transcurre desde la sospecha diagnóstica de cáncer hasta el inicio del tratamiento definitivo. | Días | 150.00 | 2015 | 2021 | P | 100.00 |
| | | | | | | A | |

Details

Means of verification: Sistema de Información de Tamizaje

Pro-Gender No

Pro-Ethnicity No

The General Development
bjective indicator target is
expected to be observed by
the operation's "Fully
Justified" date
in Convergence (CO)

No

| | Indicator | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | | Target |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|------------------------------|---|--------|
| 0.0 | Personas de entre 40 y 65 años que utilizaron servicios de salud en el último mes, sobre el total de personas en el mismo rango etario y periodo de tiempo que utilizaron dichos servicios o que no lo hicieron habiendo tenido síntomas o problemas de salud | Porcentaje | 75.00 | 2013 | 2021 | P | 79.30 |
| | | | | | | A | |

Details

Means of verification: Este indicador se mide a través del estudio de impacto de Redes, sobre la base de las Encuestas Nacionales de Factores de Riesgo 2005, 2009, 2013 y 2018.

Pro-Gender No

Pro-Ethnicity No

The General Development
bjective indicator target is
expected to be observed by
the operation's "Fully
Justified" date
in Convergence (CO)

No

PMR Public Report

RESULTS MATRIX

Specific Development Objectives

Specific Development Objectives Nbr. 0: Incrementar el acceso efectivo de la población con cobertura pública exclusiva a servicios de tamizaje para la detección oportuna de enfermedades crónicas o del riesgo de contraerlas

Observation:

| Indicator | | Unit of Measure | Baseline | Baseline Year | | 2018 | 2019 | 2020 | 2021 | EOP 2021 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|---|-------|------|-------|------|----------|
| 0.0 | Porcentaje de personas mayores de 40 años con CPE con RCGV mayor de 10, que efectuaron consultas de seguimiento en el último año | Porcentaje | 9.00 | 2016 | P | 10.68 | | 12.20 | | 12.20 |
| | | | | | A | 7.50 | | 10.40 | | 10.40 |

Details

Means of verification: Sistema de Información Sanitario Argentino (SISA)

| | | | |
|------------|----|---------------|----|
| Pro-Gender | No | Pro-Ethnicity | No |
|------------|----|---------------|----|

| Indicator | | Unit of Measure | Baseline | Baseline Year | | 2018 | 2019 | 2020 | 2021 | EOP 2021 |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------|---------------|---|------------|------------|------|------|------------|
| 0.1 | Personas a las que se realiza al menos un tamizaje para riesgo cardiovascular o cánceres de mama, cervicouterino y colorrectal en CAPS cubiertos por el programa | # of beneficiaries | 0.00 | 2015 | P | 250,000.00 | 200,000.00 | | | 450,000.00 |
| | | | | | A | 231,574.00 | 345,733.00 | | | 577,307.00 |

Details

Means of verification: Informes semestrales

| | | | |
|------------|----|---------------|----|
| Pro-Gender | No | Pro-Ethnicity | No |
|------------|----|---------------|----|

| Indicator | | Unit of Measure | Baseline | Baseline Year | | 2018 | 2019 | 2020 | 2021 | EOP 2021 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|---|------|-------|------|------|----------|
| 0.2 | Personas entre 40 y 65 años que reportan haber tenido al menos una medición de presión arterial en los últimos dos años sobre el total de personas del mismo grupo etario | Porcentaje | 72.00 | 2013 | P | | 76.50 | | | 76.50 |
| | | | | | A | | 80.27 | | | 80.27 |

Details

Means of verification: Informe de evaluación de impacto del Programa REDES

| | | | |
|------------|----|---------------|----|
| Pro-Gender | No | Pro-Ethnicity | No |
|------------|----|---------------|----|

| Indicator | | Unit of Measure | Baseline | Baseline Year | | 2018 | 2019 | 2020 | 2021 | EOP 2021 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|---|------|-------|------|------|----------|
| 0.3 | Personas entre 40 y 65 años que alguna vez tuvieron una medición de glucemia sobre el total de personas del mismo grupo etario. | Porcentaje | 74.00 | 2013 | P | | 78.40 | | | 78.40 |
| | | | | | A | | 79.25 | | | 79.25 |

Details

Means of verification: Informe de evaluación de impacto del Programa REDES

| | | | |
|------------|----|---------------|----|
| Pro-Gender | No | Pro-Ethnicity | No |
|------------|----|---------------|----|

PMR Public Report

RESULTS MATRIX

Specific Development Objectives

| Indicator | | Unit of Measure | Baseline | Baseline Year | | 2018 | 2019 | 2020 | 2021 | EOP 2021 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|---|------|------|-------|------|----------|
| 0.4 | Mujeres entre 50 y 69 años con al menos una mamografía en los últimos 24 meses, sobre el total de mujeres del mismo grupo etario | Porcentaje | 8.12 | 2015 | P | | | 10.00 | | 10.00 |
| | | | | | A | | | 11.50 | | 11.50 |

Details

Means of verification: Reportes del Sistema de Información de Tamizaje

| | | | |
|-------------------|----|----------------------|----|
| Pro-Gender | No | Pro-Ethnicity | No |
|-------------------|----|----------------------|----|

| Indicator | | Unit of Measure | Baseline | Baseline Year | | 2018 | 2019 | 2020 | 2021 | EOP 2021 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|---|------|-------|-------|------|----------|
| 0.5 | Mujeres entre 30 y 64 años con al menos un tamizaje de cáncer cervicouterino según guías de práctica clínica , sobre el total de mujeres del mismo rango etario | Porcentaje | 17.00 | 2015 | P | | | 20.40 | | 20.40 |
| | | | | | A | | 24.00 | 5.00 | | 5.00 |

Details

Means of verification: Reportes del Sistema de Información de Tamizaje

| | | | |
|-------------------|----|----------------------|----|
| Pro-Gender | No | Pro-Ethnicity | No |
|-------------------|----|----------------------|----|

| Indicator | | Unit of Measure | Baseline | Baseline Year | | 2018 | 2019 | 2020 | 2021 | EOP 2021 |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|---|------|------|------|------|----------|
| 0.6 | Personas entre 50 y 75 años con al menos un tamizaje de cáncer colorrectal en los últimos dos años, sobre el total de personas del mismo rango etario en las provincias | Porcentaje | 5.00 | 2015 | P | | | 6.60 | | 6.60 |
| | | | | | A | | | 7.70 | | 7.70 |

Details

Means of verification: Reportes del Sistema de Información de Tamizaje

| | | | |
|-------------------|----|----------------------|----|
| Pro-Gender | No | Pro-Ethnicity | No |
|-------------------|----|----------------------|----|

| Indicator | | Unit of Measure | Baseline | Baseline Year | | 2018 | 2019 | 2020 | 2021 | EOP 2021 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|---|-------|-------|-------|------|----------|
| 0.7 | Porcentaje de las consultas en el Primer Nivel de Atención que requieren una prescripción medicamentosa que se obtiene a través de REMEDIAR. | Porcentaje | 26.20 | 2018 | P | 26.20 | 25.50 | 26.20 | | 26.20 |
| | | | | | A | | | 26.20 | | 26.20 |

Details

Means of verification: Sistema Integrado de reportes de logística y medicamentos, REMEDIAR.

Observations: Fórmula de cálculo: Numerador: Número de consultas que reciben el medicamento gratuitamente por el programa. Denominador: Número total de consultas que reciben una prescripción en el PNA.

| | | | |
|-------------------|----|----------------------|----|
| Pro-Gender | No | Pro-Ethnicity | No |
|-------------------|----|----------------------|----|

PMR Public Report

RESULTS MATRIX

Specific Development Objectives

| Indicator | | Unit of Measure | Baseline | Baseline Year | | 2018 | 2019 | 2020 | 2021 | EOP 2021 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-----------------|---------------|---------------|---|------|------|------|------|----------|
| 0.8 | Plan de implementación de una vacuna contra la COVID-19 elaborado o fortalecido | Plan | 0.00 | 2020 | P | | 0.00 | 1.00 | | 1.00 |
| | | | | | A | | | 1.00 | | 1.00 |
| Details | | | | | | | | | | |
| Means of verification: Fuente de la información: Ministerio de Salud | | | | | | | | | | |
| Observations: En 2020, se redireccionó recursos de la operación para financiar el anticipo de la opción de compra de vacunas contra el COVID-19 del Mecanismo COVAX. En ese contexto, el Ministerio de Salud ha preparado y publicado un plan de implementación de la vacunación contra covid-19. | | | | | | | | | | |
| Pro-Gender | | No | Pro-Ethnicity | | | | No | | | |

Specific Development Objectives Nbr. 1: Incrementar las competencias de los efectores del Primer Nivel de Atención para la detección oportuna o el tratamiento de enfermedades crónicas

Observation:

| Indicator | | Unit of Measure | Baseline | Baseline Year | | 2018 | 2019 | 2020 | 2021 | EOP 2021 |
|----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|---------------|----------|----------|----------|------|----------|
| 1.0 | Personal del Primer Nivel de Atención que demuestra tener al menos 80% de los conocimientos en estrategias de mejora de los cuidados de salud | Personas | 0.00 | 2016 | P | 1,890.00 | | 3,780.00 | | 3,780.00 |
| | | | | | A | 1,970.00 | 2,717.00 | 2,717.00 | | 2,717.00 |
| Details | | | | | | | | | | |
| Means of verification: Informe de evaluación de capacitaciones | | | | | | | | | | |
| Pro-Gender | | No | | | Pro-Ethnicity | | No | | | |

| Indicator | | Unit of Measure | Baseline | Baseline Year | | 2018 | 2019 | 2020 | 2021 | EOP 2021 |
|----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|---------------|----------|----------|----------|------|----------|
| 1.1 | Médicos del Primer Nivel de Atención que demuestran tener al menos 60% de los conocimientos en Terapéutica Racional de Medicamentos | Personas | 1,800.00 | 2015 | P | 4,034.00 | 5,800.00 | 7,600.00 | | 7,600.00 |
| | | | | | A | 733.00 | 2,126.00 | 2,126.00 | | 2,126.00 |
| Details | | | | | | | | | | |
| Means of verification: Informe de Evaluación de Capacitaciones | | | | | | | | | | |
| Pro-Gender | | No | | | Pro-Ethnicity | | No | | | |

| Indicator | | Unit of Measure | Baseline | Baseline Year | | 2018 | 2019 | 2020 | 2021 | EOP 2021 |
|-----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------|---------------|---|----------|----------|----------|------|----------|
| 1.2 | Agentes sanitarios que demuestran tener al menos 80% de los conocimientos en prevención y detección temprana de cáncer en el Primer Nivel de Atención | Personas | 0.00 | 2015 | P | 1,900.00 | | | | 3,645.00 |
| | | | | | A | 590.00 | 1,448.00 | 1,356.00 | | 2,858.00 |
| Details | | | | | | | | | | |
| Means of verification: Informes de evaluación de capacitaciones | | | | | | | | | | |

PMR Public Report

RESULTS MATRIX

Specific Development Objectives

| | | | |
|------------|----|---------------|----|
| Pro-Gender | No | Pro-Ethnicity | No |
|------------|----|---------------|----|

RESULTS MATRIX

OUTPUTS: ANNUAL PHYSICAL AND FINANCIAL PROGRESS

Component Nbr. 1 Fortalecimiento del Primer Nivel de Atención

| | Output | Unit of Measure | | PHYSICAL PROGRESS | | FINANCIAL PROGRESS | |
|-----|---------------------------------------------------------------------------------------------------------------------------------|------------------------|------|-------------------|------------|--------------------|------------|
| | | | | 2021 | EOP 2021 | 2021 | EOP 2021 |
| 1.1 | Proyectos Jurisdiccionales de Inversión bajo la modalidad REDES 3 ejecutados | Jurisdicciones por año | P | 0 | 24 | 0 | 66,966,965 |
| | | | P(a) | 24 | 24 | 0 | 42,638,375 |
| | | | A | 24 | 24 | 5,118,541 | 47,756,916 |
| 1.2 | Proyectos Innovadores de REDES en ejecución | Proyectos | P | 0 | 10 | 0 | 186,000 |
| | | | P(a) | 6 | 6 | 0 | 24,429 |
| | | | A | 5 | 5 | 22,800 | 47,229 |
| 1.3 | Informes de carga de recetas finalizados | Informes | P | 0 | 2 | 0 | 1,450,000 |
| | | | P(a) | 0 | 1 | 0 | 287,946 |
| | | | A | 0 | 1 | 0 | 287,946 |
| 1.4 | Personal Sanitario capacitado en Terapéutica Racional, Cuidado de Medicamentos y en Operatoria del Programa CUS Medicamentos | Personas | P | 0 | 15,000 | 0 | 5,424,129 |
| | | | P(a) | 4,330 | 18,259 | 0 | 695,082 |
| | | | A | 4,445 | 18,374 | 2,102 | 697,184 |
| 1.5 | Personal del Primer Nivel de Atención capacitado en estrategias de mejora de los cuidados de salud | Personas | P | 0 | 4,200 | 0 | 2,468,490 |
| | | | P(a) | 0 | 4,028 | 0 | 198,657 |
| | | | A | 0 | 4,028 | 5,813 | 204,470 |
| 1.6 | Plan de Proyectos de Implementación-Acción de REDES III finalizados | Proyectos | P | 0 | 10 | 0 | 2,000,000 |
| | | | P(a) | 4 | 4 | 0 | 152,791 |
| | | | A | 4 | 4 | 84,601 | 237,392 |
| 1.7 | Tratamientos de medicamentos esenciales distribuidos en Centros del Primer Nivel de Atención | Tratamientos | P | | 0 | | 0 |
| | | | P(a) | 0 | 28,751,629 | 28,000,000 | 42,043,252 |
| | | | A | 11,133,934 | 39,885,563 | 0 | 14,043,252 |
| 1.8 | Jurisdicciones con estrategias de inversión para fortalecer la capacidad de respuesta frente al coronavirus COVID-19 ejecutadas | Jurisdicciones por año | P | | 0 | | 0 |
| | | | P(a) | 0 | 24 | 132,125 | 33,356,774 |
| | | | A | 0 | 24 | 201,863 | 33,426,512 |
| 1.9 | Adhesión de Argentina en el Mecanismo COVAX | pago | P | | 0 | | 0 |
| | | | P(a) | | 1 | 0 | 28,117,000 |
| | | | A | 0 | 1 | 0 | 28,117,000 |

RESULTS MATRIX

OUTPUTS: ANNUAL PHYSICAL AND FINANCIAL PROGRESS

Component Nbr. 2 Fortalecimiento de la línea de cuidados oncológicos

| | Output | Unit of Measure | | PHYSICAL PROGRESS | | FINANCIAL PROGRESS | |
|-----|------------------------------------------------------------------------------------------------------------|-----------------|------|-------------------|----------|--------------------|------------|
| | | | | 2021 | EOP 2021 | 2021 | EOP 2021 |
| 2.1 | Hospitales que registran en el Sistema de Información de Tamizaje | Hospitales | P | 0 | 46 | 0 | 7,033,274 |
| | | | P(a) | 0 | 59 | 132,963 | 2,378,138 |
| | | | A | 18 | 77 | 97,640 | 2,342,815 |
| 2.2 | Hospitales que registran en el Registro Institucional de Tumores de Argentina | Hospitales | P | 0 | 50 | 0 | 4,464,594 |
| | | | P(a) | 5 | 18 | 38,333 | 714,875 |
| | | | A | 5 | 18 | 27,963 | 704,505 |
| 2.3 | Hospitales que registran en el Registro Oncopediátrico Hospitalario | Hospitales | P | 0 | 39 | 0 | 434,935 |
| | | | P(a) | 1 | 21 | 10,167 | 147,817 |
| | | | A | 0 | 20 | 7,152 | 144,802 |
| 2.4 | Pruebas para virus de papiloma humano distribuidas. | Kits | P | 0 | 326,070 | 0 | 13,113,481 |
| | | | P(a) | 0 | 252,858 | 1,258,858 | 6,283,195 |
| | | | A | 60,192 | 313,050 | 1,336,206 | 6,360,543 |
| 2.5 | Pruebas de sangre oculta distribuidas | Kits | P | 0 | 435,000 | 0 | 2,467,324 |
| | | | P(a) | 0 | 155,775 | 19,549 | 243,007 |
| | | | A | 93,250 | 249,025 | 5,376 | 228,834 |
| 2.6 | Agentes sanitarios capacitados en prevención y detección temprana de cáncer en el Primer Nivel de Atención | Personas | P | 0 | 5,115 | 0 | 616,857 |
| | | | P(a) | 0 | 3,813 | 0 | 16,096 |
| | | | A | 325 | 4,138 | 0 | 16,096 |
| 2.7 | Informe de evaluación del Proyecto Piloto de Cuidados Paliativos | Informe | P | 0 | 1 | 0 | 794,498 |
| | | | P(a) | 0 | 1 | 2,000 | 126,557 |
| | | | A | 0 | 1 | 1,792 | 126,349 |

Other Cost

| | | | | | | |
|--|-----------------------------------------------------|------|--|--|-----------|------------|
| | Administración y auditoría | P | | | 0 | 4,628,932 |
| | | P(a) | | | 242,987 | 1,959,412 |
| | | A | | | 166,802 | 1,883,227 |
| | Gastos administrativos REDES | P | | | 2,946,475 | 16,336,142 |
| | | P(a) | | | 213,910 | 4,212,751 |
| | | A | | | 30,002 | 4,028,843 |
| | Gastos administrativos CUS-Medicamentos | P | | | 2,446,474 | 11,635,749 |
| | | P(a) | | | 0 | 2,403,846 |
| | | A | | | 11,505 | 2,415,351 |
| | Fortalecimiento para la implementación del registro | P | | | 0 | 899,061 |
| | | P(a) | | | 0 | 0 |
| | | A | | | | 0 |

Total Cost

| | | | | | | |
|--|------------|------|--|--|------------|-------------|
| | Total Cost | P | | | 5,392,949 | 166,000,000 |
| | | P(a) | | | 30,050,892 | 166,000,000 |
| | | A | | | 7,120,158 | 143,069,266 |

PMR Public Report

CHANGES TO THE MATRIX

| Section | Name | Type of Change | Subtype | Modified By | Entered in the System |
|---------|---------------------------------------------|----------------|--------------------|-------------|-----------------------|
| Output | Proyectos Innovadores de REDES en ejecución | Modify Output | Modify Output name | IGNEZT | 10/06/2021 |

RISKS AND PLANNED RESPONSES

| Risk ID | Risk Status | | Risk Taxonomy |
|---------|------------------|---------------------|---------------|
| 1 | Active | | N/A |
| | | | |
| | Response actions | | |
| | 1.1 | Management Strategy | Status |
| | | - | |
| | | | |
| | 1.2 | Management Strategy | Status |
| | | - | |
| | | | |
| | 1.3 | Management Strategy | Status |
| | | - | |
| | | | |

| Risk ID | Risk Status | | Risk Taxonomy |
|---------|------------------|---------------------|---------------|
| 2 | Active | | N/A |
| | | | |
| | Response actions | | |
| | 2.1 | Management Strategy | Status |
| | | - | |
| | | | |

IMPLEMENTATION STATUS AND LEARNING

| Lesson Learned - Categories |
|---------------------------------------------------------|
| Others - Dimensions Related to Public Processes/ Actors |
| Others - Fiduciary Dimensions |
| Others - Technical-Sectorial Dimensions |